Angelo Maiolino

Instituição:

Universidade Federal do Rio de Janeiro

Centro:

Centro de Ciências da Saúde

Unidade:

Faculdade de Medicina

Departamento:

Departamento de Clínica Médica/FM

ORCID:

não disponível no Lattes


Formação:

  • Universidade Federal do Rio de Janeiro

    Clínica Médica | Doutorado | 1995 - 2001

  • Universidade Federal do Rio de Janeiro

    Clínica Médica | Mestrado | 1991 - 1995
Laboratórios:
Nenhum laboratório cadastrado
Nuvens de Palavras:
Artigos:

(78.69% artigos com DOI)

Titulo DOI Ano
Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: subgroup analysis 10.1002/ajh.26602 2023
Lenalidomide Maintenance and Measurable Residual Disease in a Real-World Multiple Myeloma Transplanted Population Receiving Different Treatment Strategies Guided by Access to Novel Drugs in Brazil 10.3390/cancers15051605 2023
Editorial: Minimal residual disease (MRD) assessment in multiple myeloma patients 10.3389/fonc.2023.1211935 2023
Adipose Tissue-Derived Stromal/Stem Cells Transplantation with Cholecalciferol Supplementation in Recent-Onset Type 1 Diabetes Patients: Twelve Months Follow-Up 10.1055/a-2094-1039 2023
Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study 10.1016/s2352-3026(23)00243-0 2023
COVID-19 in multiple myeloma patients: frequencies and risk factors for hospitalization, ventilatory support, intensive care admission and mortality -cooperative registry from the Grupo Brasileiro de Mieloma Multiplo (GBRAM) 10.1016/j.htct.2023.08.002 2023
Comparison between computed tomography and magnetic resonance imaging in detecting multiple myeloma lesions in the skull: A systematic review 10.1007/s40336-023-00605-0 2023
EE227 Waldenstrom's Macroglobulinemia: An Overview of Treatment Patterns, Resource Use, and Costs From the Brazilian Private Healthcare Perspective 10.1016/j.jval.2023.09.495 2023
Incorporação de medicamentos no SUS: comparação entre oncologia e componente especializado da assistência farmacêutica 10.1590/1413-81232022276.16282021 2022
Guidelines on the diagnosis and management of multiple myeloma treatment: Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular Project guidelines: Associação Médica Brasileira - 2022. Part I 10.1016/j.htct.2022.06.003 2022
Blinatumomabe em pacientes pediátricos com leucemia linfoblástica aguda B em primeira recidiva de alto risco: um estudo de custo-efetividade 10.21115/jbes.v14.n1.p41-50 2022
Application of EBMT, MASCC and qSOFA scores to predict complicated febrile neutropenia and mortality in autologous stem cell transplant recipients 10.56875/2589-0646.1034 2022
CAR-T cell therapy for multiple myeloma: a practical toolkit for treatment in Brazil 10.1016/j.htct.2022.08.002 2022
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group 10.1016/S1470-2045(20)30756-7 2021
B-Cell Regeneration Profile and Minimal Residual Disease Status in Bone Marrow of Treated Multiple Myeloma Patients 10.3390/cancers13071704 2021
Adipose tissue-derived stromal/stem cells + cholecalciferol: a pilot study in recent-onset type 1 diabetes patients 10.20945/2359-3997000000368 2021
Cancer patients diagnosed with COVID-19 infection: a multicenter retrospective cohort of nine Brazilian cancer centers 10.5935/2526-8732.20210013 2021
The Brazilian Association of Hematology, Hemotherapy and Cellular Therapy seeks the implementation of, and access to, the CAR-T cell treatment in Brazil 10.1016/j.htct.2021.07.001 2021
Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial 10.1016/s0140-6736(21)00592-4 2021
Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. IV: CAR-T cell therapy for multiple myeloma patients 10.1016/j.htct.2021.09.004 2021
Pre-engraftment Cytomegalovirus DNAemia after allogeneic hematopoietic stem cell transplantation and its impact on engraftment 10.1038/s41409-021-01520-6 2021
COVID and hematology: special considerations regarding patient safety, gold standard therapies and safety for health care professionals 10.1016/j.htct.2020.04.001 2020
Managing patients with multiple myeloma during the COVID-19 pandemic: recommendations from an expert panel - ABHH monoclonal gammopathies committe 10.1016/j.htct.2020.05.001 2020
Allogenic Adipose Tissue-Derived Stromal/Stem Cells and Vitamin D Supplementation in Patients With Recent-Onset Type 1 Diabetes Mellitus: A 3-Month Follow-Up Pilot Study 10.3389/fimmu.2020.00993 2020
What is the role of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) in the scenario of new drugs for Multiple Myeloma (MM) 10.46765/2675-374X.2020v1n1p27-29 2020
International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials 10.1038/s41375-020-01012-4 2020
Results of the daratumumab monotherapy early access treatment protocol in patients from Brazil with relapsed or refractory multiple myeloma 10.1016/j.htct.2020.07.005 2020
Imaginological characterization of multiple myeloma lesions of the jaws through cone-beam computed tomography 10.1007/s11282-019-00394-1 2019
Polymorphisms in the CIITA −168A/G (rs3087456) and CIITA +1614G/C (rs4774) may influence severity in multiple sclerosis patients 10.1590/0004-282x20190026 2019
New proteasome inhibitors in the treatment of multiple myeloma 10.1016/j.htct.2018.07.003 2019
Survival differences in multiple myeloma in Latin America and Asia: a comparison involving 3664 patients from regional registries 10.1007/s00277-019-03602-4 2019
Oral health status of patients with multiple myeloma 10.1016/j.htct.2019.01.012 2019
Superiority of the triple combination of bortezomib, cyclophosphamide and dexamethasone versus cyclophosphamide, thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma, eligible for transplantation 10.1016/j.htct.2019.05.004 2019
Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy 10.1182/blood.2019002610 2019
Bisphophonate alterations of the jaw bones in individuals with multiple myeloma 10.1259/dmfr.20190155 2019
Up-front autologous hematopoietic stem cell transplantation (AHSCT) from a single Brazilian center 10.1038/s41409-019-0659-1 2019
Minimal residual disease and quality sample evaluation by Next Generation Flow cytometry in multiple myeloma patients: a Brazilian experience 10.1016/j.clml.2019.09.299 2019
Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial 10.1016/S0140-6736(18)33003-4 2019
Analysis of Availability and Access of Anti-myeloma Drugs and Impact on the Management of Multiple Myeloma in Latin American Countries 10.1016/j.clml.2018.08.005 2018
The frequency of oral conditions detected in hematology inpatients 10.1016/j.htct.2018.02.006 2018
Can dentists detect multiple myeloma through oral manifestations? 10.1016/j.bjhh.2017.08.006 2018
Unmet needs in multiple myeloma in Brazil from physicians? perspective - barriers in quality of life and disease management 10.21115/jbes.v10.n2.p165-171 2018
Observational study of multiple myeloma in Latin America 10.1007/s00277-016-2866-9 2017
Paradoxes of hematology: When the old disappears and the new does not arrive 10.1016/j.bjhh.2017.01.001 2017
Multiple Myeloma Cells Express Key Immunoregulatory Cytokines and Modulate the Monocyte Migratory Response 10.3389/fmed.2017.00092 2017
Autologous hematopoietic cell transplantation for multiple myeloma patients with renal insufficiency: a center for international blood and marrow transplant research analysis 10.1038/bmt.2017.198 2017
Genetic aberrations in multiple myeloma characterized by cIg-FISH: a Brazilian context 10.1590/1414-431x20155034 2016
Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma 10.1016/j.bbmt.2016.11.011 2016
Invasive fungal diseases in patients with acute lymphoid leukemia 10.3109/10428194.2016.1154957 2016
Phase 3 trial of three thalidomide-containing regimens in patients with newly diagnosed multiple myeloma not transplant-eligible 10.1007/s00277-015-2537-2 2016
Risk factors for invasive fusariosis in patients with acute myeloid leukemia and in hematopoietic cell transplant recipients 10.1093/cid/ciu947 2015
Risk factors for invasive mold diseases in allogeneic hematopoietic cell transplant recipients 10.1111/tid.12328 2015
Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation 10.1038/bmt.2015.190 2015
Early and late oral features of chronic graft-versus-host disease 10.5581/1516-8484.20140012 2014
Randomized Double-Blind Clinical Trial Comparing Clobetasol And Dexamethasone For The Topical Treatment Of Symptomatic Oral Chronic Graft Versus Host Disease 10.1016/j.bbmt.2014.04.009 2014
Older Patients with Myeloma Derive Similar Benefit from Autologous Transplantation 10.1016/j.bbmt.2014.07.013 2014
Interaction between IL-6 and TNF-α genotypes associated with bacteremia in multiple myeloma patients submitted to autologous stem cell transplantation (ASCT) 10.1016/j.lrr.2014.05.002 2014
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Siltuximab (Anti-IL-6 mAb) and Bortezomib versus Bortezomib Alone in Patients with Relapsed or Refractory Multiple Myeloma 10.1002/ajh.23868 2014
Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry 10.3324/haematol.2012.067272 2013
Salvage Second Hematopoietic Cell Transplantation In Myeloma 10.1016/j.bbmt.2013.01.004 2013
Biodistribution of bone marrow mononuclear cells after intra-arterial or intravenous transplantation in subacute stroke patients 10.2217/rme.13.2 2013
Guidelines on the diagnosis and management of multiple myeloma treatment: Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular Project guidelines: Associação Médica Brasileira - 2012 10.5581/1516-8484.20130050 2013
Ciprofloxacin prophylaxis in high risk neutropenic patients: effects on outcomes, antimicrobial therapy and resistance 10.1186/1471-2334-13-356 2013
Oral status of patients submitted to autologous hematopoietic stem cell transplantation 10.1007/s00520-013-1940-2 2013
Thalidomide plus dexamethasone as a maintenance therapy after autologous hematopoietic stem cell transplantation improves progression-free survival in multiple myeloma 10.1002/ajh.23274 2012
Risk factors for unsuccessful peripheral blood stem cell harvesting using granulocyte-colony stimulating factor mobilization in patients with multiple myeloma 10.1016/j.transci.2012.06.013 2012
Challenges for medical residency in hematology and transfusion medicine in Brazil 10.5581/1516-8484.20120081 2012
Clinical response to interferon beta and glatiramer acetate in multiple sclerosis patients: a Brazilian cohort 10.1590/S0004-282X2012001000005 2012
Bone marrow mononuclear cell therapy for patients with cirrhosis: a Phase 1 study 10.1111/j.1478-3231.2010.02424.x 2011
Effect of obesity on outcomes after autologous hematopoietic stem cell transplantation for multiple myeloma 10.1016/j.bbmt.2011.05.005 2011
Trends in allogeneic stem cell transplantation for multiple myeloma: a Center for International Blood and Marrow Transplant Research (CIBMTR) analysis 10.1182/blood-2011-02-337329 2011
Oral involvement of chronic graft-versus - host disease in hematopoietic stem cell transplantation 2011
The AIBE and the new phase of the RBHH 10.5581/1516-8484.20110003 2011
Acute myeloid leukemia: update in diagnosis and treatment in Brazil 10.1590/s1679-45082011ao1853 2011
Migration and homing of bone-marrow mononuclear cells in chronic ischemic stroke after intra-arterial injection 10.1016/j.expneurol.2009.10.010 2010
Low-power laser to prevent oral mucositis in autologous hematopoietic stem cell transplantation 10.1111/j.1600-0609.2009.01336.x 2010
Race and Outcomes of Autologous Hematopoietic Cell Transplantation for Multiple Myeloma 10.1016/j.bbmt.2009.11.007 2010
Methylation status of nine tumor suppressor genes in multiple myeloma 10.1007/s12185-009-0459-2 2010
Cryopreservation of peripheral blood stem cell: the influence of cell concentration on cellular and hematopoietic recovery 10.1111/j.1537-2995.2010.02743.x 2010
Biodistribution of bone marrow mononuclear cells in chronic chagasic cardiomyopathy after intracoronary injection 10.1016/j.ijcard.2010.02.008 2010
Transplante de células-tronco hematopoéticas em gamopatias monoclonais 10.1590/S1516-84842010005000017 2010
Serum ferritin as risk factor for sinusoidal obstruction syndrome of the liver in patients undergoing hematopoietic stem cell transplantation 10.1182/blood-2009-03-212282 2009
High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program 10.1111/j.1365-2141.2008.07409.x 2009
High CD8+ lymphocyte dose in the autograft predicts early absolute lymphocyte count recovery after peripheral hematopoietic stem cell transplantation 10.1002/ajh.21314 2009
Factors associated with bacteremia due to multidrug-resistant Gram-negative bacilli in hematopoietic stem cell transplant recipients 10.1590/S0100-879X2009000300010 2009
Early Tissue Distribution of Bone Marrow Mononuclear Cells After Intra-Arterial Delivery in a Patient With Chronic Stroke 10.1161/CIRCULATIONAHA.109.863084 2009
Risk assesment for multiple myeloma:preliminary results of the brazilian myeloma study group 2008
Mieloma múltiplo: qual o grau de conhecimento sobre a doença em medicos que atuam no sistema de atenção primaria a saúde 2008
Confirmation of the utility of the International Staging System and identification of a unique pattern of disease in Brazilian patients with multiple myeloma 10.3324/haematol.11637 2008
O transplante autólogo de células- tronco hematopoéticas no tratamento do mieloma múltiplo 2007
Mieloma múltiplo e insuficiência renal 2007
Mieloma múltiplo: Progressos e desafios 2007
Epidemiology of bacteremia and factors associated with multi-drug-resistant gram-negative bacteremia in hematopoietic stem cell transplant recipients 10.1038/sj.bmt.1705677 2007
Risk assessment for multiple myeloma: the role of bone marrow transplantation 2006
High-dose sequential chemotherapy versus less intensive regimen followed by peripheral blood autilogous hematopoietic stem cell transplantation as salvage treatment in relapsed and refractory Hodgkin´s disease 2006
Estudo retrospectivo do tratamento da leucemia mieloide aguda com o transplante de medula óssea - A experiência brasileira 2006
Frontline Therapy with Early Intensification and Autologous Stem Cell Transplantation versus Conventional Chemotherapy in Unselected High-Risk, Aggressive Non-Hodgkin?s Lymphoma Patients: A Prospective Randomized GEMOH Report 10.1159/000089460 2006
Validation of the EBMT risk score in chronic myeloid leukemia in Brazil and allogeneic transplant outcome 2005
A non-randomized comparative study using different doses of acyclovir to prevent herpes simplex reactivation in patients submitted to autologous stem cell transplantation 10.1590/S1413-86702005000400010 2005
Editorial: Associação Italo-Brasileira de Hematologia (AIBE). 2004
Critérios Clinicos e Achados Laboratorias do Diagnóstico das Gamopatias Monoclonais 2004
Fatores Prognósticos no Mieloma Múltiplo 2004
TMO para mieloma múltiplo em situações especiais: insuficiência renal e no idoso 2004
Fusarium Infection in Hematopoietic Stem Cell Transplant Recipients 10.1086/383319 2004
Prophylactic meropenem during neutropenia in allogeneic stem cell transplant recipients 10.1038/sj.bmt.1704459 2004
Strongyloidiasis pre and post autologous peripheral blood stem cell transplantation 10.1038/sj.bmt.1704309 2004
Successful treatment of oral lesions of chronic lichenoid graft-vs.-host disease by the addition of low-level laser therapy to systemic immunosuppression 10.1046/j.0902-4441.2003.00202.x 2004
Engraftment syndrome following autologous hematopoietic stem cell transplantation: definition of diagnostic criteria 10.1038/sj.bmt.1703855 2003
Infectious complications in patients randomized to receive allogeneic bone marrow or peripheral blood transplantation 10.1111/j.1399-3062.2003.00033.x 2003
Outcome predictors of 84 patients with hematologic malignancies andFusarium infection 10.1002/cncr.11510 2003
A randomized multicenter study of G-CSF starting on day +1 vs day +5 after autologous peripheral blood progenitor cell transplantation 2002
Hematopoietic stem cell transplantation in the treatment of multiple myeloma. 2002
Infecções em transplante de medula óssea 2000
Delayed G-CSF after bone marrow transplantation 1998
Caftazidime plus amikacin plus teicoplanin or vancomycin in the empirical antibiotic therapy in febrile neutropenic cancer patients 1998
Comparing an apple to a fruit salad 1997
Clinical factors predictive of bone marrow involvement in Hodgkins Disease 1997
Cutaneous involvement of sustemic fungal infections in neutropenic patients 1992
Cyclosporin A and chronic graft versus host disease 1990
Bone Marrow Transplantation for acute non lymphoid leukemia (ANLL) in first remission? an update 1989
Intravenous imunoglobulin in transplant patients 1988
Estudo da Imunidade Celular e Humoral na Sarcoidose e na Tuberculose. 1982
Eventos:

(0.00% eventos com DOI)

Titulo DOI Ano
How I Treat Multiple Myeloma 2019
Treatment of relapsed or refractory multiple myeloma 2018
Impact of Treatment on B-Cell Regeneration By Next Generation Flow Cytometry in Patients with Multiple Myeloma 2018
Carbapenem-resistant enterobacteriaceae colonization-importance in the risk of CRE bacteremia and mortality in stem cell transplant (HSCT) and acute leukemia? 2018
Multiple Myeloma Profile in Latin America: Clinical and Epidemiology Observational Study 2013
IL-10 haplotypes associated with infection susceptibility in autologous bone marrow transplantation in multiple myeloma patients 2012
Regional differences in the treatment approaches for relapsed multiple myeloma: An IMF study. 2012
A phase III study comparing thalidomide/cyclophosphamide/dexa vs thalidomide/dexa vs thalidomide/melphalan/prednisone in de novo multiple myeloma patients not eligible for ASCT. A three years follow -up 2011
Multiple Myeloma profile in Latin America: A web-based clinical and epidemiological observational study(preliminary results) 2011
Transplante autólogo - taxa de falha na mobilização de células hematopoéticas e influência do agente mobilizador 2011
Reduced-intensity alogeneic stem cell transplantation for relapsed /refractory Hodgkin's lymphoma: no benefit for graft - versus-lymphoma effect 2011
Microvessel density (MVD) in multiple myeloma patients: comparativy analysis of two different endothelial markers 2011
A phase III study comparing CTD vs TD vs MPT on de novo multiple myeloma not elegible for ASCT: Preliminary aanalysis 2010
Fatores preditivos para coleta de linfócitos em pacientes com mieloma múltiplo submetidos a mobilização de células - tronco hematopoéticas 2010
Incompatibilidade no sistema ABO em transplante de células - tronco hematopoéticas 2010
Transplante autólogo de células tronco hematopoéticas do sangue periférico: Avaliação das subpopulações de linfócitos T 2010
Oral lesions, salivary flow and mouth opening among patients diagnosed for chronic graft-versus-host disease in Rio de Janeiro/Brazil 2010
Saúde bucal de pacientes com mieloma múltiplo com indicação de uso de bisfosfonatos 2010
A phase III study comparing thalidomide/cyclophosphamide/dexa vs thalidomide/dexa vs thalidomide/melphalan/prednisone in de novo multiple myeloma patients not eligible for ASCT. A preliminary analysis 2010
Thalidomide + Dexamethasone after ASCT improves PFS in Multiple Myeloma. A Brazilian Randomized Trial 2009
Perfil das condições bucais de pacientes candidatos ao transplante autólogo de células -tronco hematopoéticas 2009
Thalidomide + Dexamethasone as maintenance after single autologous stem cell transplantation improves progression -free survival cin advanced multiple myeloma. A prospective Brazilian randomized trial 2009
Ciprofloxacina profilática para pacientes con câncer e neutropenia: Impacto no desfecho clinico e em resistencia microbina 2009
Uso da galactomanana para pesquisa de infecção fungica em pacientes hematológicos- Dados preliminares 2009
Leucemia mieloide aguda : Avaliação nacional de exames diagnósticos e protocolos de tratamento 2009
Estudo prospectivo randomizado fase III aberto multicentrico : Talidomida + ciclofosfamida + dexa vs talidomida + dexa vs talidomida + melfalan + prednisona em pacientes com mieloma multpilo não elegivies para tmo 2009
Thalidomide plus dexamethasone as maintenance after single autologous stem cell transplantation improves progression-free survival in advanced multiple myeloma . A prospective Brazilian randomized trial 2009
Thalidomide + dexamethasone as maintenance after single autotlogous stem cell transplantation improves progression -free survival in advanced multiple myeloma . A prospective brazilian randomized trial 2008
Ciprofloxacina profilática para pacientes com câncer e neutropenia : Impacto no desfecho clínico e em resitência antimiceobiana 2008
Transplante autólogo de células-tronco hematopoéticas do sangue periférico. Influência da concentração celular criopreservada na recuperação celular e hematopoética 2008
ISS was highly predictive of prognosis in a Brazilian study in myeloma patients 2008
Ciprofloxacin prophylaxis in neutropenic patients at a center with high rates of Gram-negative bacteremia 2007
Should CD34+ cells for stem cell mobilization be between 7-10 cells/ml 2007
Questão social: desafios e contribuições de uma categoria profissional no TCTH 2007
Mieloma Múltiplo: Diferenciação de células dendríticas a partir de monócitos 2007
Análise da viabilidade celular por citometria de fluxo e microscopia ótica em produtos de células -tronco hematopoéticas do sangue periférico criopreservados 2007
Transplante autólogo de células-tronco hematopoéticas: Análise de variáveis do procedimento de criopreservação na recuperação do transplante 2007
Should number of circulating CD34+cells that permit blood stem cell mobilization for autologous peripheral transplantation be lower than 10 cells/mm3 2007
Is hypercalcemia an idependent prognostic factor in Brazilian patients with multiple myeloma 2007
Infection in multiple myeloma: Preliminary results of a multicenter prospective study 2007
Staphylococcal bacteremia in neutropenic patients: Epidemiology, susceptibility and its impact on the outcome 2007
Preliminary Safety and Efficacy Results from an International Phase 3b Study for Expanded Acess to Bortezomib in 624 Patients with Relapse and/or Refractory Multiple Myeloma. 2006
Hypermethylation of DAP-K is an Adverse Prognostic Factor in Patients with Multiple Myeloma (MM) 2006
Osteonecrose dos maxilares em terapia com bifosfonatos- Experiência nacional multidisciplinar 2006
Functionality and Phenotypic Profile of Monocyte-Derived Dendritic Cells from Patients with Multiple Myeloma 2006
Análise das Células Mononucleares do Sangue Periférico em Pacientes portadores de Mieloma Múltiplo após Transplante autólogo de Medula Óssea 2006
Avaliação da Doença Enxerto Contra-Hospedeiro Crônica nos Pacientes Submetidos a Transplante de Células Progenitoras Hematopoéticas Alogênico em Nossa Instituição 2006
Bacteremia Estafilocócica (BE) durante a neutropenia: mudanças atuais da epidemiologia e da susceptibilidade e seu impacto clínico 2006
Bloodstream Infections due to Gram-Negative Bacteria (GN) among Stem Cell Transplant (HSCT) Recipients: Prevalence and Clinical Importance 2006
Experiência no Tratamento de Pacientes com Leucemia Mielóide Aguda (LMA) Submetidos a Transplante de Células Progenitoras Hematopoéticas em Nossa Instituição 2006
Fatores Associados à Mortalidade Relacionada ao Transplante (TRM) Autólogo após Alta Dose de Quimioterapia 2006
Fatores de Risco e Prognóstico de Bacteremia por Gram-Negativo Multi-REsistente (GN-MDR) no Transplante de Medula Óssea 2006
Infecção da Corrente Sanguínea por Bactérias Gram-Negativas (GN) em Pacientes Submetidos a Transplante de Medula Óssea (TMO): Prevalência e Impotância Clínica 2006
Profilaxia com Quinolona no Paciente Neutropênico: de Volta a Antiga Questão? 2006
Púrpura Amegacariocítica como Manifestação Auto-Imune na Doença Enxerto vs Hopedeiro Crônica 2006
Risk Factors and Outcome Associated With Multi-Drug Resistance Gram-Negative (MDR-GN) Bacteremia in Neutropenic Hematopoetic Stem Cell Transplant Recipients 2006
Risk Factors and Outcome Associated with Multi-Drug Resistance Gram-Negative (MDR-GN) Bacteremia in Neutropenic Hematopoietic Stem Cell Transplant (HSCT) Recipients 2006
Staphylococcal Bacteremia (SB) During Neutropenia: Current Trends in Epidemiology and Susceptibility and Its Impact on the Outcome 2006
Tranplante Alogeneico de Intensidade Reduzida em Linfomas Não-Hodgkin Avançados em Recaída Pós-Transplante Autólogo ou Refratários: Impacto do Regime de Condicionamento 2006
Transplante de medula óssea com incompatibilidade ABO maior: A tolerância imunológica pode condicionar a presença simultânea de quimera eritrocitária e aglutininas circulantes? 2006
Multiple myeloma (MM) in Brazil: Clinical and demographic features and the utiity of ISS in 1017 patients mosttly with advanced disease 2006
Factors associated with clinical outcomes of 483 allogeneic peripheral blood stem cell transplant (PBSCT) in Brazil. 2005
Non-myeloablative transplant is an independent risk factor for bacteremia due to resistant gram-negative organisms: preliminary results of a multicenter survey. 2005
Persistent bacteremia in neutropenic patients: prevalence and clinical significance 2005
South America multiple myeloma study: epidemiological and clinical characteristics of 751 patients. 2005
Autologous Haematopoietic stem cell transplantation for the treatment of multiple myeloma: a multicenter retrospective study. 2005
Factors associated with clinical outcomes of 483 allogeneic peripheral blood stem cell transplant (PBSCT) in Brazil. 2005
Bacteremia persistente em pacientes neutropênicos: prevalência e importância clinica. 2005
Terapia de salvamento com transplante de células prognitoras hematopoéticas (TCPH) em doença de Hodgkin (DH):Comparação entre duas etratégias com ou sem utilização de terapia seqüencial em altas doses. 2005
Minitransplante alogeneico em linfomas avançados: evidencia do efeito graft versus limphoma (GVL). 2005
ABO-incompatible bone marrow transplantation (BMT) and ABH platelet (PLT) high expression may be implicated in the delay PLT count recovery. 2005
Uso de quinolona profilática na neutropenia: de volta à antiga questão? 2005
Epidemiologia de bacteremias por gram-negativo (GN) em trasnplante de células progenitoras hematopoéticas (TCPH): resultados de um estudo multicêntrico brasileiro. 2005
Cateter não tunelizado em transplante autólogo: Uma opção mais barata e segura. 2005
A presença de quimerismo misto (QM) no D+90 após ALO-TMO mieloablativo é um fator prognóstico desfavorável em pacientes com leucemia mielóide crônica. 2005
Clinical outcome of alogeneic peripheral blood stem cell transplants (PBSCT) in acute myeloid leukemia (AML). 2005
Transfusão autóloga em doadores de medula óssea (MO). 2005
Clinical outcome of allogeneic peripherical blood stem cell transplants (PBSCT) in acute lymphoblastic leukemia (ALL). 2005
Bacteremia persistente em pacientes neutropênicos: Prevalência e importância clínica. 2005
Uso de quinolona profilática na neutropenia: de volta a antiga questão? 2005
Estudo de alterações cromossômicas com valor prognóstico desfavorável em pacientes com mieloma múltiplo. 2005
Estudo fase 3 cooperativo multicentrico para tratamento do mieloma múltiplo recém diagnosticado. Estratégia baseada no risco> Resultados preliminares 2005
Estudo retrospectivo do mieloma múltiplo em centros brasileiros - Aspectos epidemilogicos - Resultados preliminares. 2005
Padrão da metilação de múltiplos gens supressores de tumor em pacientes com mieloma múltiplo. 2005
Validation of the international staging system for multiple myeloma: A retrpospective analisis of 487 patients at 8 brazilian centers. 2005
Resistant Gram-Negative bacteremia in hematopoetic stem cell transplant (HSCT) recipients: incidence and autcome. 2004
Factors associated with clinical outcomes of 483 allogeneic peripheral blood stem cell transplants (PBSCT) in Brazil. 2004
Allogeneic hematopoietic stem cell transplantation - EBMT risk score evaluation for chronic myeloid leukemia in Brazil 2004
Allogeneic haematopoetic stem cell transplantation- EBMT risk score evaluation for 1084 CML patients transplanted in Brazil. 2004
Prospective randomized study comparing 12-week VACOP-B regimen versus 6-week VACOP-B plus high-dose sequential followed by autologous boné marrow transplantation in high-risk IPI agressive non-Hodgkin Lymphoma. A Brazilian GEMOH report 2004
Transplante alogênico com células precursoras periféricas (CPP) - Experiência brasileira. 2004
Grupo de estudo de TMO em mieloma múltiplo.Transplante de céluas-tronco hematopoéticas (TCPH) no mieloma múltiplo (MM): análise multicêntrica retrospectiva em instituições brasileiras. 2004
Terapia antifúngica preemptiva em transplante de células progenitoras hematopoéticas (TCPH)- uma nova abordagem. 2004
Minitransplante alogenico para linfomas avançados: evidências do efeito gat versus lymphoma (GVL). 2004
Mobilização de células CD34+CD7+ para sangue periférico- relato de caso. 2004
Transfusão de granulócitos em paciente com neutropenia prolongada. 2004
Estudo de alterações cromossômicas com valor prognóstico em pacientes com mieloma múltiplo (MM). Pré-tratamento com quimioterapia em alta dose e transplante de células hematopoéticas. 2004
Apresentação atípica de DECH após utilização do protocolo Flag-Ida como resgate de recaída LMA M7 após transplante alogênico de medula óssea- relato de caso. 2004
Transplante autólogo de células progenitoras hematopoéticas (TACPH) no tratamento de doença de Hodgkin (DH): resultados de 56 casos do HUCFF-UFRJ. 2004
Curso clinico atípico em leucemia mielóide crônica (LMC) com duplo cromossomo Philadelphia (Ph) expressando como único transcrito BCR-ABL a isoforma e1a2. 2004
Doença enxerto contra hospedeiro cutânea com apresentação psoriasiforme. 2004
Propsective randomized study comparing conventional chemotherapy and high-dose escalation followed by autologous hematopoetic stem cell transplantation (AHSCT) in unselected high-risk IPI NHL. 2004
Allogeneic hematopoietic stem cell transplantation (alloHSCT)- EBMT risk score (RS) evaluation for 1084 CML patients transplanted in Brazil. 2004
Prospective randomized study comparing conventional chemotherapy and high-dose escalation followed by autologous hematopoietic stem cell transplantation (AHCST) in unselected high-risk IPI NHL. 2004
Características epidemiológicas e clinicas de 541 pacientes com mieloma múltiplo de seis instituições brasileiras. 2004
Transplante alogênico com células precursoras periféricas (CPP)- Experiência brasileira. 2004
Infections complications in patients randomized to receive allogeneic bone marrow or peripheral blood transplantation. 2003
Prospective randomized study comparing the third generation VACOP-B regiments versus 6 weeks VACOP-B plus high-dose sequential followed by autologous boné marrow transplantation in unselected high-risk IPI non Hodgkin` Lymphoma. A Gemoh report. 2003
Infiltração hepática de mieloma múltiplo após transplante autólogo de progenitores hematopoéticos. Correlação clinico-biológica. 2003
Infiltração hepática por plesmócitos em paciente com mieloma múltiplo com recaída após transplante autólogo de medula óssea 2003
Detecção de células neoplasicas por citometria de fluxo e PCR em pacientes com mieloma múltiplo. 2003
Infections complications in patients randomized to receive allogeneic boné marrow or peripheral blood transplantation. 2003
Diferentes estratégias para detecção de deleção 13q14 em pacientes com mieloma múltiplo. 2003
Eletrolyte abnormalities during large volume stem cell collection for PBSC transplantation. 2003
Variables associated with eletrolyte imbalance during large-volume PBSC collection. 2003
Prospective randomized study comparing the third generation VACOP-B regimens versus 6 week VACOP-B plus high-dose sequential followed by autologous bone marrow transplantation in unselaected high-risk IPI non Hodgkin`s lymphoma. A GEMOH report. 2003
Talidomida + dexametasona (Tal/dex) no tratamento de recaída após transplante autólogo de células progenitoras hematopoéticas (TACPH) em pacientes com mieloma múltiplo. 2003
Relato de caso: tratamento de lesões oris da doença enxerto-contra-hospedeiro crônica (DECHc) liquenóide pela adição do laser da baixa intensidade (LBI) á terapia imunossupressora. 2003
Influência de doença de base no padrão de infecções após transplante autólogo de células progenitoras hematopoéticas (TACPH). 2003
Infecções por bactérias resistentes em transplante de células progenitoras hematopoéticas (TCPH). 2003
Análise dos episódios de febre e neutropenia ocorridos durante a mobilização de células progenitoras hematopoéticas. 2003
Transplante de medula óssea (TMO): acompanhamento imuno-hematológico. 2003
Relação de células CD23+/UFC-GM em diversas fontes de células tronco-hematopoéticas para transplante. 2003
Uso combinado de GM-CSF e IFN- na obtenção de células dendríticas. 2003
Infections complications in patients randomized to receive allogeneic bone marrow or peripheral blood transplantation. 2002
Systemic fusarium infection in bone marrow transplant. 2002
Variables associated with electrolyte imbalance during PBSC collection for BMT. 2002
Eletrolyte abnormalities during large-volume stem cell collection for bone marrow transplantation. 2002
Unselected high - risk IPI NHL presented a high early mortality in a prospective randomized study comparing conventional chemotherapy and high-dose escalation followed by autologous bone marrow transplantation. 2002
Infecção sistêmica por Fusarium spp em receptores de transplante alogenico de células progenitoras. 2002
Systemic fusarium inefction in bone marrow transplant recipients 2002
Eficiência da coleta de células progenitoras com baixas contagens de CD34+ para transplante autólogo de medula óssea. 2002
Unselected high-risk IPI NHL presented a high early mortality rate in a prospective randomized study comparing conventional chemotherapy and high-dose escalation followed by autologous bone marrow transplantation. 2002
Autologous peripheral blood progenitor cells transplantation for the treatment of multiple myeloma. 2001
Incidence and factors associated with engraftment syndrome in autologous stem cell transplantation. 2001
Influence of patients characteristics on CD34+yeld in large volume stem cell collection for autologous bone marrow transplantation. 2001
Large volume stem cell collection efficiency for patients with low pré apheresis CD32+ counts. 2001
Unselected high-risk IPINHL presented a high early mortality rate in a prospective randomized study comparing conventional chemotherapy and high-dose escalation followed by autologous bone marrow transplantation. 2001
Síndrome da pega (SP) após transplante autólogo de células tronco-hematopoéticas (TAMO). 2001
Estudo Epidemiológico multicêntrico de infecção por Fusarium sp. Em pacientes com leucemia e transplante de medula óssea. 2001
Epidemiologia de infecção pelo vírus varicelazoster (VZV) em pacientes submetidos a transplante autólogo de células progenitoras (TAMO). 2001
Resultados do tratamento de 54 pacientes com mieloma múltiplo (MM) utilizando quimioterapia em altas doses seguido de transplante autólogo com células tronco-hematopoéticas (TAMO). 2001
Estudo multicentrico randomizado comparando o uso de filgastrima (GCSF) a partir do dia +1 ou dia +5 após autotransplante de células progenitoras de snague periférico (TCPSP). 2001
Resultado do tratamento de 54 pacientes com mieloma múltiplo (MM) utilizando quimioterapia em altas doses seguido de transplante autólogo com células tronco hematopoéticas (TAMO). 2001
Preliminary results of a randomized multicenter study comparing the use of granulocyte colony - stimulating factor (G-CSF) on day + 1 or Day + 5 after autologous peripheral blood progenitor cell transplants. 2000
A randomized, multicenter study of G-CSF starting on day+1 versus day+5 after autologous peropheral blood progenitor cell transplantation. 2000
Incidence and factors associated with the engraftment syndrome in autologous stem cell transplantation. 2000
Autologous peripheral blood progenitor cells transplantation for the treatment of multiple myeloma. 2000
Contaminação microbiológica na coleta, na manipulação laboratorial e na reinfusão de células progenitoras hamatopoéticas. 2000
Avaliação prospectiva da imunidade celular de pacientes submetidos a transplante autólogo de células tronco progenitoras (TACTP). 2000
Fatores associados com a duração da febre em pacientes submetidos a transplante autólogo de células tronco progenitoras. 1999
Avaliação prospectiva da recuperação da imunidade celular de pacientes submetidos a transplante autólogo de células tronco progenitoras (TACTP). 1999
Transplante autólogo utilizando células progenitoras do sangue periférico. Experiência no Hospital Universitário da Universidade Federal do rio de Janeiro 1999
Quimioterapia em altas doses seguido de transplante autólogo com células progenitoras hematopoiéticas no tratamento do mieloma múltiplo. 1999
Ensino de hematologia: comparação entre curso baseado em aulas e um curso baseado em problemas. 1999
Quimioterapia em altas doses seguido de transplante autólogo com células progenitoras hematopoiéticas no tratamento do Mieloma Múltiplo. 1998
Prevalência de Herpes Zoster em pacientes submetidos a quimioterapia em altas doses seguido de transplante autólogo com células progenitoras hematopoiéticas. 1998
Utilização da associação de ciclofosfamida 1,5 g/m2 e G-CSF 10 mcg/kg/dia para a mobilização de células progenitoras do sangue periférico. 1998
Quimioterapia em altas doses seguido de transplante autólogo com células progenitoras hematopoiéticas no tratamento dos Linfomas . 1998
Quimioterapia em altas doses seguida de resgate com células progenitoras hematopoéticas no tratamento dos linfomas. 1997
Transplante autólogo de células progenitoras do sangue periférico: Experiência do Hospital Universitário da Universidade Federal do Rio de Janeiro. 1997
Estenose cicatricial por Doença de Crohn complicando curso de transplante autólogo de células progenitoras do sangue periférico: Relato de caso. 1997
Fatores prognósticos em pacientes com febre e neutropenia. 1997
Transplante autólogo de medula óssea e/ou células progenitoras do sangue periférico. Dois anos de experiência no Hospital Universitário Clementino Fraga Filho da Universidade Federal do Rio de Janeiro. 1996
Transplante autólogo de células progenitoras do sangue periférico. Experiência do Hospital Universitário Clementino Fraga Filho da Universidade Federal do Rio de Janeiro 1996
Transplante autólogo de medula óssea: determinação de UFC-GM como indicador prognóstico da recuperação hematopoiética . 1996
Fatores Preditivos de Infiltração de Medula Óssea na Doença de Hodgkin. 1996
Síndrome Hemolítico Uremica: Uma complicação tardia do transplante autólogo de células progenitoras hematopoiéticas. Relato de caso. 1996
Estrongiloidiase em pacientes com hemopatias malignas: Um estudo transversal. 1996
Risk Factors for Superinfections in Febrile Neutropenic Patients. 1995
Pele Frouxa Granulomatosa, Um Subtipo Raro de Linfoma T Cutâneo: Relato de Um Caso. 1995
Resultados Iniciais do Tratamento da Doença de Hodgkin em Recaída com Transplante de Medula Óssea Autólogo. 1995
Fatores prognósticos para óbito por infecção em pacientes com leucemia mielóide aguda. 1995
Transplante de Medula Óssea Autólogo: Análise da Celularidade e GM.CFU na coleta e Criopreservação de Medula Óssea. 1995
Acute Myeloid Leukemia - Thirteen Years Follow- Up in a Single Institution in Rio de Janeiro. 1994
Padronização de Ensaio Clonogênico para Unidades Formadoras de Colônias de Granulócitos e Macrófagos com Células de Medula Óssea Utilizando o Meio Condicionado da Linhagem 5637. 1994
Tratamento da Anemia Aplástica com Globulina Anti - Linfocitária, Ciclosporina e Metilprednisolona. Relato de Dois Casos. 1994
Superinfecções em Pacientes com Febre e Neutropenia. 1994
Causas de óbito em pacientes com leucemia/linfoma T (Atl). Relato de 5 casos. 1994
Superinfecções em pacientes com febre e neutropenia. 1994
Leucemia Mielóide Aguda - Dificuldades e Progressos em 13 anos de tratamento no Hospital Universitário Clementino Fraga Filho - Universidade Federal do Rio de Janeiro. 1993
Thalidomide for extensive chronic GVHD: a pilot study in 5 patients. 1989
A randomized trial comparing cyclosporin A-1 vs 5mg/kg/day in allogenic bone marrow transplantation. 1989
Risk factors at diagnosis and survival post-BMT in patients with chronic granulocytic leukaemia (CGL). 1989
Can cyclosporin A be definitively stopped after BMT and when. 1988
Hemopoiesis after allogenic bone marrow transplantation for leukaemia: studies using red blood cells markers. 1988
Allogenic Bone Marrow Transplantation for acute lymphoblastic leukemia. 1988
Splenic Syndrome at Mountain. Splenic Infarctation in Sickle cell trait in non-black person. 1988
Treatment of severe aplastic anemia in Genova. 1988
Alternating Promace/Mopp chemotherapy in advanced diffuse poor prognosis non-Hodgkin lymphoma (NHL). A preliminary report of the Italian Study Group (ILSG). 1987
Cytoxan + Total Body Irradiation with autologus bone marrow transplantation in adult lymphoblastic lymphoma in first complete remission. A report of the Italian Lymphoma Study Group. 1987
High-dose cyclosphosphamide, etoposide and BCNU with autologus BMT (ABMT) rescue in advanced resistant Hodgkin's disease patients. 1987
High-dose therapy (HDT) and autologus BMT (ABMT) in advanced poor-prognosis non-Hodgkin lymphoma (NHL). Italian Study Group. 1987
T cell depleted marrow transplantation: High relapse rate after removal of a small helper T subset. 1987
L'insufficienza midollare GVHD associata. 1987
Rischio di ricaduta leucemica dopo trapianto di midollo osseo allogenico. Analisi multi variata su 167 casi trapiantati a Genova 1987
Megachemioterapia + Irradiazione corporea totale e trapianto di midollo autologo in linfomi non-Hodgkin in stadio avanzato ed a cattiva prognosi. Report of NHL Cooperative Study Group. 1987
Promace/Mopp alterno nella terapia dei linfomi non-Hodgkin in stadio avanzato ed a cattiva prognosi. Rapporto preliminare del NHL Cooperative Study Group. 1987
Endoxan + Irradiazione corporea totale seguita di trapianto di midollo autologo nel linfoma linfoblastico dell'adulto in prima remissione completa. Report of NHL Cooperative Study Group. 1987
de Hodgkin - Experiência do Hospital Universitário da Universidade Federal do Rio de Janeiro. 1985
Linfoma não-Hodgkin - Experiência do Hospital Universitário da Universidade Federal do Rio de Janeiro. 1985
Leucemia Mielóide Aguda - Revisão Crítica da Experiência do Hospital Universitário da Universidade Federal do Rio de Janeiro. 1985
Publicações:
Minha Rede: